Abstracts tagged "treatment"

Abstract Number: 1298 • 2012 ACR/ARHP Annual Meeting
Improvement of Treatment Outcome of Rheumatoid Arthritis with Salazosulfapyridine by Pharmacogenetic Approach
Shunichi Kumagai¹, Yoshiaki Hagiwara², Yoshihide Ichise¹, Sho Sendo³, Nobuhiko Okada¹, Jun Saegusa⁴ and Goh Tsuji⁵, ¹Center of rheumatic diseases, Shinko hospital, Kobe, Japan, ²Department of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ³Center of rheumatic diseases, Shinko Hospital, Kobe, Japan, ⁴Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan
Background/Purpose: Salazosulfapyridine (SASP) is acetylated in liver by N-acetyltransferase2 (NAT2) in the track of metabolism. Previous studies have shown that genotyping of NAT2 is adequate…
Abstract Number: 773 • 2012 ACR/ARHP Annual Meeting
Remission Rates with Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
Josef S. Smolen¹, D. Aletaha², D. Gruben³, J. D. Bradley⁴, S. H. Zwillich³, S. Krishnaswami³, B. Benda⁵ and C. Mebus⁶, ¹Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Pfizer Inc., Groton, CT, ⁴Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, ⁵Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This analysis evaluated the rates…
Abstract Number: 369 • 2012 ACR/ARHP Annual Meeting
Differences in Short-Term Radiographic Progression Following Early Response to Adalimumab Plus Methotrexate Vs. Methotrexate Alone
Ronald F. van Vollenhoven¹, James W. Shaw², Mary A. Cifaldi³, James Signorovitch⁴, Eric Q. Wu⁴, Thomas Samuelson⁴, Elizabeth Faust⁴ and Paul Emery⁵, ¹Karolinska Institute, Stockholm, Sweden, ²Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL, ³Abbott Laboratories, Abbott Park, IL, ⁴Analysis Group, Inc., Boston, MA, ⁵Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom
Background/Purpose: To prevent disease progression, treat-to-target recommendations for rheumatoid arthritis (RA) include the evaluation and adjustment of drug therapy at least every 3 months until…
Abstract Number: 1846 • 2012 ACR/ARHP Annual Meeting
Observation of Persistence Rates and Potential Costs Savings Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis in England, Wales and Northen Ireland Clinical Practice
Mike Russell¹, Jen Timoshanko¹, Graeme Duncan², Angela Spandley¹ and Samantha Roskell³, ¹UCB Pharma, Slough, United Kingdom, ²Healthcare at Home Ltd, Burton on Trent, United Kingdom, ³Rheumatology, Cannock Chase Hospital, Cannock, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) therapy in the UK is standardized by the National Institute for Health and Clinical Excellence (NICE). To be eligible for anti-TNF…
Abstract Number: 1312 • 2012 ACR/ARHP Annual Meeting
Clinical Response At 12 Weeks Predicts Long-Term Remission and the Extent of Radiographic Progression in Japanese Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol with and without Methotrexate Coadministration
Tsutomu Takeuchi¹, Kazuhiko Yamamoto², Hisashi Yamanaka³, Naoki Ishiguro⁴, Yoshiya Tanaka⁵, Katsumi Eguchi⁶, Akira Watanabe⁷, Hideki Origasa⁸, Toshiharu Shoji⁹, Nobuyuki Miyasaka¹⁰ and Takao Koike¹¹, ¹Keio University School of Medicine, Tokyo, Japan, ²Department of Allergy & Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, ⁵The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶Sasebo City General Hospital, Sasebo, Nagasaki, Japan, ⁷Research Division for Development of Anti-Infectious Agents, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan, ⁸Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ⁹Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku, Tokyo, Japan, ¹⁰Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ¹¹Sapporo medical center NTT EC, Sapporo, Japan
Background/Purpose: The majority of patients (pts) with active rheumatoid arthritis (RA) have previously been shown to respond during the first 12 weeks (wks) of certolizumab…
Abstract Number: 774 • 2012 ACR/ARHP Annual Meeting
A CD4+ T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis
Arthur G. Pratt¹, Philip M. Brown², Simon J. Cockell³, Gillian Wilson⁴ and John D. Isaacs¹, ¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom, ³Bioinformatics Unit, Newcastle University, Newcastle-upon-Tyne, United Kingdom, ⁴Directorate of Musculoskeletal Medicine, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom
Background/Purpose: The mechanism of action of methotrexate (MTX) in the management of rheumatoid arthritis (RA) remains incompletely understood. It is nonetheless capable of inducing clinical…
Abstract Number: 331 • 2012 ACR/ARHP Annual Meeting
PDL241, a Novel Humanized Monoclonal Antibody, Reveals CD319 As a Therapeutic Target for Rheumatoid Arthritis
Michel P.M. Vierboom¹, Jacky Woo², Hakju Kwon², Debra Chao², Shiming Ye², Jianmin Li², Karen Lin², Irene Tang², Nicole Belmar², Taymar Hartman², Elia Breedveld¹, Bert A. ‘t Hart¹ and Gary C. Starling², ¹Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, ²Abbott Biotherapeutics, Redwood City, CA
Background/Purpose: Current therapies have shown tremendous progress in the treatment of rheumatoïd arthritis (RA). However, a substantial group of RA patients are still refractory to…
Abstract Number: 1829 • 2012 ACR/ARHP Annual Meeting
Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance
Machaon Bonafede¹, Crystal Watson², George Joseph², Nicole Princic¹ and David J. Harrison², ¹Thomson Reuters Healthcare, Cambridge, MA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Tumor Necrosis Factor Inhibitors (TNFi) are the mainstay of treatment for rheumatoid arthritis (RA) in patients with moderate to severe disease. The three most…
Abstract Number: 1279 • 2012 ACR/ARHP Annual Meeting
First in Human Study with Recombinant Anti-IL-21 Monoclonal Antibody in Healthy Subjects and Patients with Rheumatoid Arthritis
Stanislav Ignatenko¹, Birte K. Skrumsager², Adam Steensberg³ and Ulrik Mouritzen³, ¹Charité Research Organization GmbH, Berlin, Germany, ²Clinical Pharmacology Biopharm, Novo Nordisk A/S, Copenhagen, Denmark, ³Medical & Science, Inflammation, Novo Nordisk A/S, Copenhagen, Denmark
Background/Purpose: Interleukin-21 (IL-21), a cytokine produced by activated T cells (especially T17 and TFH cells), has a proinflammatory and pleiotropic nature, and drives mainly activation…
Abstract Number: 776 • 2012 ACR/ARHP Annual Meeting
A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission
Katerina Chatzidionysiou¹, Carl Turesson², Annika Teleman³, Ann Knight⁴, Elisabet Lindqvist⁵, Per Larsson⁶, Lars Cöster⁷, Barbro Rydberg⁸, Ronald F. van Vollenhoven⁹ and Mikael Heimbürger¹⁰, ¹Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Department of Rheumatology, Spenshult Hospital, Oskarstrom, Sweden, ⁴Dept of Rheumatology, Institution for Medical Sciences, Uppsala University, Uppsala, Sweden, ⁵Department of Clinical Sciences, Section for Rheumatology Lund University, Lund, Sweden, ⁶Dept of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁷Department of Rheumatology, University Hospital, Linköping, Sweden, ⁸Department of Rheumatology, Kärnsjukhuset, Skövde, Sweden, ⁹Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, ¹⁰Medical department, Abbott Scandinavia, Stockholm, Sweden
Background/Purpose: Treatment with TNF blockers, once started as therapy for RA, is usually continued indefinitely. Information about the possibility to discontinue anti-TNF therapy in RA…
Abstract Number: 336 • 2012 ACR/ARHP Annual Meeting
Preclinical Development of ALX-0061, an Anti-IL-6R Nanobody^®For Therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile
Maarten Van Roy¹, Hans Ulrichts², Stefaan Rossenu², Sandy Jacobs², Sofie Poelmans³, Gert Verheyden², Michel Vierboom⁴, Bert 't Hart⁴, Judith Baumeister¹ and Josefin-Beate Holz⁵, ¹Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ²Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ³Pharmacology, Ablynx NV, Gent, Belgium, ⁴Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, ⁵Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor IL-6R. IL-6 plays an important role in the…
Abstract Number: 1831 • 2012 ACR/ARHP Annual Meeting
Evaluation of the Cost-Effectiveness of Rheumatoid Arthritis Treatment with Biologic Agents Using the IORRA Cohort Database
Eiichi Tanaka¹, Eisuke Inoue², Daisuke Hoshi³, Akiko Kobayashi², Naoki Sugimoto², Kumi Shidara², Eri Sato³, Yasushi Inoue³, Yohei Seto², Ayako Nakajima⁴, Shigeki Momohara³, Atsuo Taniguchi² and Hisashi Yamanaka³, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA), a chronic inflammatory disorder, causes a significant decrease in quality of life. Recently developed biologic agents (BAs) have caused a considerable…
Abstract Number: 1283 • 2012 ACR/ARHP Annual Meeting
Effects of Tofacitinib On Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Receiving Stable-Dose Methotrexate: Results of Two Phase 3 Studies
Gerd Burmester¹, Désirée van der Heijde², Vibeke Strand³, Cristiano A. F. Zerbini⁴, Carol A. Connell⁵, Charles A. Mebus⁵, Samuel H. Zwillich⁶, John D. Bradley⁵, David Gruben⁵ and Gene Wallenstein⁵, ¹Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁴Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. The efficacy and safety of…
Abstract Number: 771 • 2012 ACR/ARHP Annual Meeting
Discontinuation of Adalimumab without Functional and Radiographic Damage Progression After Achieving Sustained Remission in Patients with Rheumatoid Arthritis (the HONOR study): 1-Year Results
Yoshiya Tanaka¹, Shintaro Hirata¹, Shunsuke Fukuyo¹, Masao Nawata², Satoshi Kubo², Kunihiro Yamaoka² and Kazuyoshi Saito¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Discontinuing anti-TNF therapy after achieving a stable low disease activity (LDA) or remission (REM) state in rheumatoid arthritis (RA) has become an important area…
Abstract Number: 349 • 2012 ACR/ARHP Annual Meeting
Preliminary Results From a Controlled Study Assessing the Humoral Immune Response to Vaccines in Rheumatoid Arthritis Patients Treated with Tocilizumab
Clifton O. Bingham III¹, Warren C. Rizzo², Micki Klearman³, Azra Hassanali⁴, Ruchi Upmanyu⁵ and Alan J. Kivitz⁶, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Advanced Arthritis Care & Research, Scottsdale, AZ, ³Genentech Inc, South San Francisco, CA, ⁴Genentech Inc, San Francisco, CA, ⁵Roche, Welwyn Garden City, United Kingdom, ⁶Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Tocilizumab (TCZ) is an IL-6–receptor inhibitor for treatment of rheumatoid arthritis (RA) patients (pts). Because TCZ may impact how IL-6 modulates T-cell activation and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].